Cargando…
Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection—A Single Center Survey
Background: Previous research has shown different effects of hematological malignancies on the outcome of patients with COVID-19 infection depending on the type of disease and the treatment received. This research was aimed at examining the clinical outcome of COVID-19 infection in positive patients...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10533142/ https://www.ncbi.nlm.nih.gov/pubmed/37763683 http://dx.doi.org/10.3390/medicina59091564 |
_version_ | 1785112128000098304 |
---|---|
author | Ćojbašić, Irena Golubović, Ivana Ćojbašić, Žarko |
author_facet | Ćojbašić, Irena Golubović, Ivana Ćojbašić, Žarko |
author_sort | Ćojbašić, Irena |
collection | PubMed |
description | Background: Previous research has shown different effects of hematological malignancies on the outcome of patients with COVID-19 infection depending on the type of disease and the treatment received. This research was aimed at examining the clinical outcome of COVID-19 infection in positive patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Methods: We collected retrospective information on chronic myeloid leukemia patients who were treated and monitored in our institution during the pandemic period. Within this cohort, we recorded COVID-19 positive symptomatic patients and analyzed their basic characteristics, symptoms, severity, and outcome. Results: In the study cohort when COVID-19 was diagnosed, 86.7% of patients were on first-generation tyrosine kinase inhibitors therapy—imatinib. At the time of infection, 70% of patients were in molecular remission, 23.4% in complete cytogenetic remission, and 3.3% in complete hematological response. Most patients had symptomatic disease. Within the analyzed group, 56.7% of patients had asymptomatic/mild COVID-19 infection, 23.3% of patients had moderate symptoms which did not require hospitalization, and 20% of patients had severe/critical symptoms that required admission to the intensive care unit. More than half of the patients interrupted treatment with tyrosine kinase inhibitors temporarily during COVID-19. There were no deaths due to COVID-19 infection. Conclusions: In compliance with other larger clinical studies, analysis of the clinical outcome of COVID-19 infection in patients with chronic myeloid leukemia on tyrosine kinase inhibitors therapy in this study showed that they do not have an increased risk for COVID-19 infection and that they have a mild course of the disease with recovery. |
format | Online Article Text |
id | pubmed-10533142 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105331422023-09-28 Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection—A Single Center Survey Ćojbašić, Irena Golubović, Ivana Ćojbašić, Žarko Medicina (Kaunas) Article Background: Previous research has shown different effects of hematological malignancies on the outcome of patients with COVID-19 infection depending on the type of disease and the treatment received. This research was aimed at examining the clinical outcome of COVID-19 infection in positive patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Methods: We collected retrospective information on chronic myeloid leukemia patients who were treated and monitored in our institution during the pandemic period. Within this cohort, we recorded COVID-19 positive symptomatic patients and analyzed their basic characteristics, symptoms, severity, and outcome. Results: In the study cohort when COVID-19 was diagnosed, 86.7% of patients were on first-generation tyrosine kinase inhibitors therapy—imatinib. At the time of infection, 70% of patients were in molecular remission, 23.4% in complete cytogenetic remission, and 3.3% in complete hematological response. Most patients had symptomatic disease. Within the analyzed group, 56.7% of patients had asymptomatic/mild COVID-19 infection, 23.3% of patients had moderate symptoms which did not require hospitalization, and 20% of patients had severe/critical symptoms that required admission to the intensive care unit. More than half of the patients interrupted treatment with tyrosine kinase inhibitors temporarily during COVID-19. There were no deaths due to COVID-19 infection. Conclusions: In compliance with other larger clinical studies, analysis of the clinical outcome of COVID-19 infection in patients with chronic myeloid leukemia on tyrosine kinase inhibitors therapy in this study showed that they do not have an increased risk for COVID-19 infection and that they have a mild course of the disease with recovery. MDPI 2023-08-28 /pmc/articles/PMC10533142/ /pubmed/37763683 http://dx.doi.org/10.3390/medicina59091564 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ćojbašić, Irena Golubović, Ivana Ćojbašić, Žarko Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection—A Single Center Survey |
title | Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection—A Single Center Survey |
title_full | Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection—A Single Center Survey |
title_fullStr | Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection—A Single Center Survey |
title_full_unstemmed | Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection—A Single Center Survey |
title_short | Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection—A Single Center Survey |
title_sort | clinical outcomes of patients with chronic myeloid leukemia and covid-19 infection—a single center survey |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10533142/ https://www.ncbi.nlm.nih.gov/pubmed/37763683 http://dx.doi.org/10.3390/medicina59091564 |
work_keys_str_mv | AT cojbasicirena clinicaloutcomesofpatientswithchronicmyeloidleukemiaandcovid19infectionasinglecentersurvey AT golubovicivana clinicaloutcomesofpatientswithchronicmyeloidleukemiaandcovid19infectionasinglecentersurvey AT cojbasiczarko clinicaloutcomesofpatientswithchronicmyeloidleukemiaandcovid19infectionasinglecentersurvey |